GILD Share Price

Open 80.00 Change Price %
High 80.71 1 Day 0.29 0.36
Low 79.56 1 Week -2.33 -2.82
Close 80.24 1 Month -2.73 -3.29
Volume 6347815 1 Year 6.83 9.30
52 Week High 86.27
52 Week Low 63.76
GILD Important Levels
Resistance 2 81.31
Resistance 1 80.87
Pivot 80.17
Support 1 79.61
Support 2 79.17
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
DEST 2.38 48.75%
HAUP 0.08 33.33%
SCHS 0.04 33.33%
SYNT 24.30 27.23%
SYNT 24.30 27.23%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Gilead Sciences, Inc. (NASDAQ: GILD)

GILD Technical Analysis 3
As on 17th Oct 2017 GILD Share Price closed @ 80.24 and we RECOMMEND Buy for LONG-TERM with Stoploss of 72.09 & Buy for SHORT-TERM with Stoploss of 79.28 we also expect STOCK to react on Following IMPORTANT LEVELS.
GILD Target for October
1st Target up-side 84.87
2nd Target up-side 87.56
3rd Target up-side 90.26
1st Target down-side 77.17
2nd Target down-side 74.48
3rd Target down-side 71.78
GILD Other Details
Segment EQ
Market Capital 51045679104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.gilead.com
GILD Address
GILD
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
GILD Latest News
Interactive Technical Analysis Chart Gilead Sciences, Inc. ( GILD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Gilead Sciences, Inc.
GILD Business Profile
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.